Publication at Faculty of Medicine in Hradec Králové |
2006
Abstract
Infliximab, monoclonal antibody against tumor necrosis factor alpha, in an effective agent in the therapy of Crohn´s disease. Although therapy with infliximab is generally well tolerated, there is an obvious concern about the effect of this treatment on the incidence of cancer.
We report a case of mucinous anorectal adenocarcinoma observed in a 39-year-old patient with long-standing Crohn´s disease after therapy with two courses of infliximab.